PMID- 25241865
OWN - NLM
STAT- MEDLINE
DCOM- 20150417
LR  - 20201209
IS  - 1673-0860 (Print)
IS  - 1673-0860 (Linking)
VI  - 49
IP  - 6
DP  - 2014 Jun
TI  - [Expression of cancer stem cell marker USP22 in laryngeal squamous cell 
      carcinoma].
PG  - 479-82
AB  - OBJECTIVE: To investigate the expression of cancer stem cell marker USP22 in 
      laryngeal squamous cell carcinoma (LSCC) and clinical implications. METHODS: The 
      expression of USP22 was detected by immunohistochemistry in LSCC tissues of 64 
      cases and squamous epithelium tissues beside carcinoma of 26 cases (control). The 
      correlation of USP22 expression with various clinicopathologic factors was 
      evaluated with the single factor analysis. RESULTS: The expression levels of 
      USP22 in LSCC and control were 57.8% and 19.2% (P < 0.05). Clinicopathological 
      analysis showed that USP22 expression level had a relationship with clinical 
      stage, T stage, and lymph node metastasis (P < 0.05), but not with gender, age, 
      smoking and differentiation (P > 0.05). Survival analysis showed that patients 
      with high USP22 expression had significantly poorer outcome compared with 
      patients with low USP22 expression. The survival was related to clinical stage, T 
      stage, and lymph node metastasis, but not with age, sex, and smoking (P > 0.05). 
      CONCLUSIONS: The expression of USP22 is significantly increased in LSCC, which 
      correlates with the malignant degree, invasion, metastasis and prognosis of LSCC. 
      USP22 may be served as a new candidate molecular marker and therapeutic target of 
      LSCC.
FAU - Li, Lijuan
AU  - Li L
AD  - Department of Otorhinolaryngology, First Clnincal Hospital of Shanxi Medical 
      University, Taiyuan 030001, China.
FAU - Wen, Shuxin
AU  - Wen S
AD  - Department of Otorhinolaryngology, First Clnincal Hospital of Shanxi Medical 
      University, Taiyuan 030001, China. Email: wensxsx@163.com.
FAU - Wang, Binquan
AU  - Wang B
AD  - Department of Otorhinolaryngology, First Clnincal Hospital of Shanxi Medical 
      University, Taiyuan 030001, China.
FAU - Gao, Wei
AU  - Gao W
AD  - Department of Otorhinolaryngology, First Clnincal Hospital of Shanxi Medical 
      University, Taiyuan 030001, China.
FAU - Zhang, Wen
AU  - Zhang W
AD  - Department of Otorhinolaryngology, First Clnincal Hospital of Shanxi Medical 
      University, Taiyuan 030001, China.
FAU - Meng, Xiaomin
AU  - Meng X
AD  - Department of Otorhinolaryngology, First Clnincal Hospital of Shanxi Medical 
      University, Taiyuan 030001, China.
FAU - Yang, Lijuan
AU  - Yang L
AD  - Department of Otorhinolaryngology, First Clnincal Hospital of Shanxi Medical 
      University, Taiyuan 030001, China.
FAU - Kong, Lingshuai
AU  - Kong L
AD  - Department of Otorhinolaryngology, First Clnincal Hospital of Shanxi Medical 
      University, Taiyuan 030001, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
JT  - Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of 
      otorhinolaryngology head and neck surgery
JID - 101247574
RN  - EC 3.1.2.- (Thiolester Hydrolases)
RN  - EC 3.4.19.12 (Ubiquitin Thiolesterase)
RN  - EC 3.4.19.12 (Usp22 protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carcinoma, Squamous Cell/*metabolism/pathology
MH  - Female
MH  - Head and Neck Neoplasms/*metabolism/pathology
MH  - Humans
MH  - Laryngeal Mucosa/*metabolism
MH  - Laryngeal Neoplasms/*metabolism/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Neoplastic Stem Cells/metabolism
MH  - Prognosis
MH  - Squamous Cell Carcinoma of Head and Neck
MH  - Thiolester Hydrolases/*metabolism
MH  - Ubiquitin Thiolesterase
EDAT- 2014/09/23 06:00
MHDA- 2015/04/18 06:00
CRDT- 2014/09/23 06:00
PHST- 2014/09/23 06:00 [entrez]
PHST- 2014/09/23 06:00 [pubmed]
PHST- 2015/04/18 06:00 [medline]
PST - ppublish
SO  - Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2014 Jun;49(6):479-82.